The Clinical Core of the Arizona ADCC is a consortium of six recruitment sites (Banner Alzheimer Institute, Barrow Neurological Institute, Mayo Clinic Arizona, Banner Sun Health Research Institute, and the University of Arizona Health Sciences Center and VA medical Center) providing catchment areas throughout the state that function as a standardized unit under a single Clinical Core Director. The Clinical Core maintains a target of 500 participants at all stages of the aging-dementia spectrum including 325 normal controls, 75 patients with mild cognitive impairment (MCI), and 100 with Alzheimer's disease (AD) and other forms of degenerative dementia. Embedded within these diagnostic categories are defined Latino and Native American cohorts. The Clinical Core capitalizes on our multi-institutional diagnostic consensus conference, centralized data management program, and close working relationships with each of the other Cores. All subjects undergo standardized diagnostic testing that: 1) fulfills strict entrance criteria;2) includes demographic, historical, medical, neurological, psychiatric, neuropsychological, and genetic measures;3) incorporates the NACC Uniform Data Set (UDS);and 4) employs culturally sensitive test procedures. Patients eligible for enrollment and those completing annual follow-up are discussed in a biweekly diagnostic consensus conference. All undergo apolipoprotein E (APOE) genotyping at entry, and an annual standardized neuropsychological battery of tests at all sites. Patient eligibility for and participation in ongoing research projects is tracked and reviewed on an ongoing basis. All are offered enrollment in the Brain Donation Program for neuropathological confirmation of clinical diagnoses, though brain donation is not required of members of culturally sensitive diversity subgroups (Latino and Native Americans). Ancillary programs of longitudinally studied aging normal controls also receive the NACC UDS supported through other funding mechanisms. These cohorts provide unique opportunities to study the transition between cognitive normality and MCI in persons at differential risk for AD and to capitalize on our strengths in maging, genomics, cognitive neuroscience, and other research methods. To address the goals of the ADCC, subjects and data from independently funded projects are now available as a resource to other researchers, being used in other studies, and will be followed prospectively using the UDS.

Public Health Relevance

The Arizona Alzheimer's Disease Center's Clinical Core includes research participants with or without certain forms of cognitive impairment, who provide DNA and blood samples, have memory and thinking tests each year, and are interested in contributing to their effort, privacy-protected information or biological samples to the scientific understanding, treatment and prevention of Alzheimer's disease. Many of the participants have voluntarily enrolled in a brain donation program, and a number of them are from Arizona's underserved and understudied Latino and Native American communities. It works closely with the other Cores and plays a critical role in the scientific fight against Alzheimer's Disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG019610-12
Application #
8379348
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
12
Fiscal Year
2012
Total Cost
$644,718
Indirect Cost
$82,748
Name
Banner Sun Health Research Institute
Department
Type
DUNS #
960181055
City
Sun City
State
AZ
Country
United States
Zip Code
85351
Mahady, Laura; Nadeem, Muhammad; Malek-Ahmadi, Michael et al. (2018) Frontal Cortex Epigenetic Dysregulation During the Progression of Alzheimer's Disease. J Alzheimers Dis 62:115-131
Caselli, Richard J; Langlais, Blake T; Dueck, Amylou C et al. (2018) Personality Changes During the Transition from Cognitive Health to Mild Cognitive Impairment. J Am Geriatr Soc 66:671-678
Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558
Liu, Li; Caselli, Richard J (2018) Age stratification corrects bias in estimated hazard of APOE genotype for Alzheimer's disease. Alzheimers Dement (N Y) 4:602-608
Allen, Mariet; Wang, Xue; Burgess, Jeremy D et al. (2018) Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. Alzheimers Dement 14:352-366
Zbesko, Jacob C; Nguyen, Thuy-Vi V; Yang, Tao et al. (2018) Glial scars are permeable to the neurotoxic environment of chronic stroke infarcts. Neurobiol Dis 112:63-78
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Caselli, Richard J; Langlais, Blake T; Dueck, Amylou C et al. (2018) Subjective Cognitive Impairment and the Broad Autism Phenotype. Alzheimer Dis Assoc Disord 32:284-290
Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2018) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord 32:10-17
Salloway, Stephen; Honigberg, Lee A; Cho, William et al. (2018) Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). Alzheimers Res Ther 10:96

Showing the most recent 10 out of 794 publications